Presentations From Progress and Controversies in Gynecologic Oncology - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations From Progress and Controversies in Gynecologic Oncology

2019 prIME, a Medscape Oncology Company Conference

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View downloadable slides from Progress and Controversies in Gynecologic Oncology: 2019 prIME, a Medscape Oncology Company Conference to get the latest information on gynecologic malignancies from the world’s leading experts.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jan 31, 2019

Expiration Date

Jan 31, 2020

Session I

Case discussion 1: Micrometastasis of 1.5 mm in lymph node (LN) in vulva cancer and frozen section–negative LN

Featured Expert: Linn Woelber, MD

Case discussion 2: One squamous cancer–positive groin LN but no primary tumor (LN CUP groin)–What to do, where to stage

Featured Expert: Luis Chiva, MD, PhD

Session II

Is there still a major role for endoscopic radical hysterectomy in cervical cancer?

Featured Expert: Ignace Vergote, MD, PhD

Management of FIGO stage I cervical cancer: Which surgical approach is used in your center?

Featured Expert: Luis Chiva, MD, PhD

Management of FIGO stage I cervical cancer: Which surgical approach is used in your center?

Featured Expert: Nicoletta Colombo, MD, PhD

Management of FIGO stage I cervical cancer: Which surgical approach is used in your center?

Featured Expert: Ignace Vergote, MD, PhD

Session III

Is immunotherapy a realistic option for the treatment of cervical and uterine cancers?

Featured Expert: Bradley J. Monk, MD, FACS, FACOG

Case discussion 3: Management of a hypercalcemic small-cell tumor of the ovary

Featured Expert: Andrés Poveda, MD

Case discussion 4: Management of a recurrent granulosa cell tumor

Featured Expert: Isabelle Ray-Coquard, MD, PhD

Changing indications for the use of PARP inhibitors in ovarian cancers: Where is it heading?

Featured Expert: Jonathan Ledermann, BSc, MD, FRCP

Tumor immunology, the biology of ovarian cancer, and treatment implications

Featured Expert: An Coosemans, MD, PhD

The impact of surgical philosophy on outcome

Featured Expert: Christina Fotopoulou, MD, PhD

Session IV

Treatment beyond progression in ovarian cancer

Featured Expert: Eric Pujade-Lauraine, MD, PhD

Case discussion 5: Treatment of recurrent ovarian cancer with a platinum treatment–free interval of 8 months

Featured Expert: Antonio González-Martín, MD, PhD

Case discussion 6: Treatment of recurrent ovarian cancer when platinum is not a good option

Featured Expert: Susana Banerjee, MBBS, MA, PhD, FRCP

Session V

Surgery for recurrent ovarian cancer: Still controversial? (DESKTOP vs GOG-213)

Featured Expert: Andreas du Bois, MD, PhD

Update on gynecologic sarcoma

Featured Expert: Jalid Sehouli, MD, PhD

Debate: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer – PRO

Featured Expert: Willemien van Driel, MD, PhD

Debate: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer – CONTRA

Featured Expert: Philipp Harter, MD, PhD

Session VI

How to integrate patient-reported outcomes and quality of life into therapy decisions

Featured Expert: Florence Joly-Lobbedez, MD, PhD

Magnitude of clinical benefit: A provocative concept in gynecologic cancer

Featured Expert: Nathan Cherny, MBBS, FRACP, FRCP

Treatment of complications: Short-term and long-term bowel effects

Featured Expert: Christoph Grimm, MD

The Progress and Controversies in Gynecologic Oncology: 2019 prIME, a Medscape Oncology Company Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners, including allied health professionals, involved in the diagnosis and management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able

  • Develop practical approaches for the management of vulvar, cervical, and endometrial cancers
  • Assess standard and emerging therapeutic options for ovarian cancer and describe how the options impact patient outcomes
  • Describe the role of novel agents in the management of gynecologic malignancies
  • Discuss strategies for the management of various rare gynecologic malignancies

This educational activity is supported by AstraZeneca, Clovis Oncology, ImmunoGen, Merck KGaA and Pfizer, and TESARO.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME, a Medscape Oncology Company for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Abu-Rustum has disclosed receipt of grants/research support from GRAIL, Olympus, and Stryker/Novadaq. He also disclosed his role as a non-paid speaker for Stryker/Novadaq. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Banerjee has disclosed receipt of grants/research support from AstraZeneca and Janssen Cilag. She has also received honoraria or consultation fees from AstraZeneca, Clovis, GamaMabs, Merck, PharmaMar, Roche, Seattle Genetics, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Cherny has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Chiva has disclosed that he has received grants or research support from AstraZeneca, Roche, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Colombo has disclosed that she has received honoraria or consultation fees from Advaxis, Amgen, AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Coosemans has disclosed that she has received grants or research support from Stand Up To Cancer (Flanders, Belgium) and C2 internal funding from KU Leuven. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr du Bois has disclosed advisory board participation/honoraria from AstraZeneca, Biocad, Clovis, Genmab, Pfizer, PharmaMar, Roche, Seattle Genetics, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fotopoulou has disclosed that she has received grants or research support from Sequana. She has also received honoraria or consultation fees from Ethicon, Olympus, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr González-Martín has disclosed receipt of honoraria or consultation fees from AstraZeneca, Clovis, PharmaMar, Roche, and Tesaro. He also participated in sponsored speaker’s bureaus for AstraZeneca, PharmaMar, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Grimm has disclosed that he has received grants or research support from Meda Pharma and Roche Diagnostics. He has also received honoraria or consultation fees from Amgen, AstraZeneca, Celgene, Merck Sharp & Dohme, PharmaMar, Roche, Tesaro, and Vifor Pharma. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harter has disclosed that he has received research funding to his institution from AstraZeneca, Boehringer Ingelheim, DFG/BMBF, DKH, European Union, GlaxoSmithKline, Medac, and Roche. He has also received honoraria or consultation fees from ASCO, AstraZeneca, Roche, Stryker, and Tesaro. He also disclosed advisory board participation for AstraZeneca, Clovis, Immunogen, Lilly, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Joly-Lobbedez has disclosed that she has received grants or research support from Astellas. She has also received honoraria or consultation fees from AstraZeneca, Bristol-Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ledermann has disclosed that he has received grants or research support from AstraZeneca and Merck Sharp & Dohme. He has also received honoraria or consultation fees from AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer, Roche, and Seattle Genetics, and participated in sponsored speaker’s bureaus for AstraZeneca and Clovis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Monk has disclosed that he has received honoraria for his role as speaker and/or consultant from Abbvie; Advaxis; Amgen; AstraZeneca; Biodesix; Clovis; Genmab; Gradalis; ImmunoGen; Immunomedics; Incyte; Janssen/Johnson&Johnson; Mateon (formerly Oxigene); Merck; Myriad; Perthera; Pfizer; Precision Oncology; Puma Biotechnology; Roche/Genentech; Samumed; Takeda; Tesaro, Inc.; and VBL. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Poveda has disclosed that he has received honoraria or consultation fees from AstraZeneca, Clovis, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pujade-Lauraine has disclosed that he has received honoraria and consultation fees from AstraZeneca, Clovis, Incyte, Pfizer, Roche, and Tesaro. He also participated in sponsored speaker’s bureaus for ARCAGY Research and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ray-Coquard has disclosed that she has received honoraria or consultation fees from AstraZeneca, Clovis, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Sehouli has disclosed that he has received grants or research support from Clovis and Tesaro. He has also received honoraria or consultation fees from AstraZeneca, Clovis, Johnson & Johnson, Pfizer, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr van Driel has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Vergote has disclosed consulting on advisory boards for Advaxis Inc, Amgen Inc, AstraZeneca NV, Bayer Pharma AG, Clovis Oncology Inc, Eisai Inc, Eli Lilly Benelux NV, F. Hoffmann-La Roche Ltd, Genmab A/S, Immunogen Inc, Mateon Therapeutics Inc, Millennium Pharmaceuticals, Morphotek Inc, Nektar Therapeutics, MSD Belgium, Novartis Pharma AG, Novocure GMBH, Oxigene Inc, Pfizer Inc, PharmaMar, Roche NV, and Vifor Pharma België NV. Dr Vergote has also disclosed that he has performed contracted research via KU Leuven for Genmab A/S – Genmab B.V. and Oncoinvent AS, and he has received grant support (corporate-sponsored research) from Amgen and Roche, and that he has received support for accommodation and travel expenses from AstraZeneca, Genmab, PharmaMar, Roche, and Takeda Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Woelber has disclosed that she has received grants or research support from Medac, Roche, and Vaccibody. She has also received honoraria or consultation fees from Jenapharm, GlaxoSmithKline, Medac, Merck Sharp & Dohme, PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME, a Medscape Oncology Company have disclosed:

  • Amy Furedy, RN, OCN (scientific content manager) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.